Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucid Diagnostics (Nasdaq: LUCD) reported third-quarter results as nationwide Medicare reimbursement for EsoGuard opened a new phase of commercialization. Revenue was $1.203 million, versus $1.211 million a year earlier. Net loss attributable to common stockholders narrowed to $6.677 million, or $0.03 per share, from $10.397 million, or $0.10 per share.
First Medicare payments arrived in October at $1,938.01 per test. Lucid performed 2,871 tests in the quarter and more than 1,800 in October, a monthly record. Cash fell to $18.0 million at September 30 from $34.7 million at December 31, 2025; a $15.0 million convertible preferred financing closed after quarter-end. Lucid expects five Concert client health plans to adopt coverage by year-end and launched its first two VA programs. A separate Medicare local coverage determination reconsideration remains pending.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointEsoGuard Medicare payments began in October at $1,938.01 per test, providing reimbursed access nationwide.
- Major pointPost-quarter private placement raised $15.0 million from existing long-term investors. 21% of market cap
- Moderate pointOctober EsoGuard volume reached a monthly record of more than 1,800 tests.
- Moderate pointQ3 common-stockholder net loss narrowed to $6.677 million from $10.397 million; loss per share fell to $0.03 from $0.10.
- Moderate pointNine-month revenue rose to $3.932 million from $3.202 million in 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Concert coverage adoption is expected at five client health plans by year-end, including three previously reported.
7 minor points
- Minor pointNine-month common-stockholder net loss narrowed to $45.020 million from $54.303 million; loss per share fell to $0.26 from $0.59.
- Minor point. Forward-looking: it has not happened yet and may not happen.Lucid launched its first two VA programs and expects VA activity to contribute meaningfully over the long term.
- Minor pointAn 11,991-patient study reported 95% sampling success, collection averaging less than two minutes and no reported device-related adverse events.
- Minor pointDraft AGA guidelines name EsoGuard and EsoCheck as an endoscopy alternative, with high certainty of evidence.
- Minor pointCost of revenues fell to $1.404 million from $1.697 million in Q3; nine-month costs also declined.
- Minor pointGeneral and administrative expenses fell to $5.536 million from $5.605 million in Q3; nine-month expenses also declined.
- Minor pointResearch and development expenses fell to $1.182 million from $1.272 million in Q3; nine-month expenses also declined.
Negative
- Major pointThe $15.0 million Series C Convertible Preferred Stock financing adds securities convertible into common shares. 21% of market cap
- Moderate pointCash declined to $18.0 million at September 30, 2026, from $34.7 million at December 31, 2025.
- Moderate pointSales and marketing expenses rose to $5.252 million from $4.291 million in Q3; nine-month expenses also increased.
- Minor pointQ3 revenue declined to $1.203 million from $1.211 million a year earlier.
- Minor pointNon-GAAP adjusted loss widened to $10.599 million from $10.300 million in Q3; nine-month loss also widened.
- Minor pointThe separate MolDX local coverage determination reconsideration remains pending.
News Explained
Medicare payments are being made through claim-by-claim adjudication, independently of the still-pending MolDX local coverage determination reconsideration; Lucid Diagnostics expects a draft determination to be published as the administrative backlog clears.
Details
Market move: PAVM -16.57% in the Nov 12 session. 3Q26 earnings report
On Nov 12, the day this news came out, PAVM closed 16.57% below the previous close. Argus tracked a trough of -12.1% from its starting point during tracking. Our momentum scanner recorded 6 alerts for this stock that day. That session’s volume was 1.6x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Nov 12 session.
Key Figures
- Medicare payment rate
- $1,938.01 per test
- Established Clinical Laboratory Fee Schedule rate; payments received on claims
- EsoGuard tests
- 2,871 tests
- 3Q26
- EsoGuard revenue
- $1.2 million
- 3Q26
- October test volume
- More than 1,800 tests
- Record monthly volume
- Operating expenses
- $13,479 thousand
- 3Q26
- Net loss attributable to common stockholders
- ($6,677 thousand)
- 3Q26, as reported
- Cash and cash equivalents
- $18.0 million
- As of September 30, 2026; compared with $34.7 million at December 31, 2025
- Series C financing
- $15.0 million
- Closed subsequent to quarter-end
Previous Earnings Reports
-
Reported $1.474 million EsoGuard revenue on 2,770 tests and expanded payer coverage.
-
Reported 3,177 EsoGuard tests and $1.256 million revenue while pursuing Medicare coverage.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
medicare administrative contractor regulatory
category iii cpt code regulatory
icd-10 diagnosis code medical
convertible preferred stock financial
gaap financial
ebitda financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
EsoGuard® now fully reimbursed by Medicare nationwide, launching a new phase of accelerating commercialization with record monthly test volume to start the fourth quarter
Conference call and webcast to be held today, November 12, at 8:30 AM EST
Conference Call and Webcast
The webcast will take place on Thursday, November 12, 2026, at 8:30 AM EST and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone,
Following the conclusion of the conference call, a replay will be available for 30 days in the investor relations section of the Company's website at luciddx.com.
Business Highlights
"Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth."
"Our pursuit of EsoGuard's enormous clinical and commercial opportunity is now substantially less constrained by external factors," Dr. Aklog added. "Lucid's near-term growth now depends almost entirely on our team's commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth. What has been a marathon is now a sprint."
Highlights from the third quarter and recent weeks:
- Received first Medicare payments for the EsoGuard® Esophageal DNA Test in October. Lucid began submitting claims in late September after meeting with medical directors at Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction over Lucid's
Texas laboratory, and providing a clinical evidence dossier incorporating their feedback. Lucid has consistently received payments on these claims at EsoGuard's established Clinical Laboratory Fee Schedule rate of per test. This Medicare coverage through claim-by-claim adjudication is independent of the pending MolDX Local Coverage Determination (LCD) reconsideration for EsoGuard.$1,938.01 - Immediately and aggressively repositioned commercial efforts to expand EsoGuard testing among at-risk Medicare beneficiaries, representing approximately half of the patients recommended for esophageal precancer testing by professional society guidelines.
- Performed 2,871 EsoGuard tests and recognized revenue of
in 3Q26. October was a record month for EsoGuard test volume, with more than 1,800 tests. More than 50,000 EsoGuard tests have been performed since launch.$1.2 million - Held a formal meeting with CMS leadership on the pending MolDX LCD reconsideration for EsoGuard. The discussion reinforced Lucid's confidence that the delay is attributable to an administrative backlog. Lucid expects the draft LCD to be published as that backlog begins to clear.
- Continued to expand commercial coverage through the Concert EsoGuard coverage policy, with a total of five Concert client health plans, including the three previously reported, expected to have formally adopted it by year-end.
- Launched Lucid's first two
U.S . Department of Veterans Affairs (VA) programs, with a robust pipeline of additional VA centers behind them. Lucid continues to expect the VA to be a meaningful long-term contributor to its commercial activity and revenue. - Announced billing and coding milestones, including a new Category III CPT code for EsoCheck cell collection and a proposed ICD-10 diagnosis code for positive EsoGuard results, which will make EsoGuard and EsoCheck easier to bill, track and integrate into clinical practice.
- Announced publication of an 11,991-patient real-world EsoGuard study, the largest peer-reviewed study of nonendoscopic esophageal precancer testing to date. Sampling with the EsoCheck® Esophageal Cell Collection Device was successful in
95% of patients and averaged less than two minutes. The procedure was well tolerated, with no reported device-related adverse events and consistent performance across operators, including newly trained personnel. - The American Gastroenterological Association (AGA) released its draft Barrett's esophagus guidelines for public comment. The draft names EsoGuard and EsoCheck as an alternative to endoscopy, with high certainty of evidence. EsoGuard is the only commercially available test cited.
- Strengthened balance sheet with a
private placement to existing long-term investors.$15.0 million
Financial Results
- For the three months ended September 30, 2026, EsoGuard related revenues were
. Operating expenses were approximately$1.2 million , which included stock-based compensation expenses of$13.5 million . GAAP net loss attributable to common stockholders was approximately$1.5 million , or$6.7 million per common share.$(0.03) - As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company's financial results, the Company's non-GAAP adjusted loss for the three months ended September 30, 2026 was approximately
or$10.6 million per common share.$(0.06) - Lucid had cash and cash equivalents of
as of September 30, 2026, compared to$18.0 million as of December 31, 2025. Subsequent to quarter end, Lucid closed a$34.7 million Series C Convertible Preferred Stock financing.$15.0 million - The unaudited financial results for the three and nine months ended September 30, 2026, were filed with the SEC on Form 10-Q on November 12, 2026, and available at www.luciddx.com or www.sec.gov.
Lucid Non-GAAP Measures
- To supplement our unaudited financial results presented in accordance with
U.S . generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA), and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense and other non-cash income and expenses, if any. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms underU.S . GAAP.
- Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our unaudited financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.
- Non-GAAP financial measures are provided to enhance readers' overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment, and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.
- A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three and nine months ended September 30, 2026, and 2025 are as follows:
|
(in thousands except per-share amounts) |
|
For the three months ended September 30, |
|
For the nine months ended September 30, |
||||
|
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
13,479 |
|
12,970 |
|
41,122 |
|
38,831 |
|
Other (Income) expense, net |
|
(5,599) |
|
(1,362) |
|
(4,917) |
|
6,115 |
|
Net Loss |
|
(6,677) |
|
(10,397) |
|
(32,273) |
|
(41,744) |
|
Net income (loss) per common share, basic and diluted |
|
|
|
|
|
|
|
|
|
Net loss attributable to common stockholders |
|
(6,677) |
|
(10,397) |
|
(45,020) |
|
(54,303) |
|
Preferred Stock dividends and deemed dividends |
|
— |
|
— |
|
12,747 |
|
12,559 |
|
Net income (loss) as reported |
|
(6,677) |
|
(10,397) |
|
(32,273) |
|
(41,744) |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
Depreciation and amortization expense1 |
|
226 |
|
220 |
|
671 |
|
663 |
|
Interest expense, net2 |
|
(58) |
|
(99) |
|
(195) |
|
(260) |
|
EBITDA |
|
(6,509) |
|
(10,276) |
|
(31,797) |
|
(41,341) |
|
|
|
|
|
|
|
|
|
|
|
Other non-cash or financing related expenses: |
|
|
|
|
|
|
|
|
|
Stock-based compensation expense3 |
|
1,451 |
|
1,152 |
|
4,555 |
|
3,326 |
|
Operating expenses issued in stock1 |
|
— |
|
87 |
|
57 |
|
234 |
|
Change in FV convertible debt2 |
|
(5,541) |
|
(2,341) |
|
(4,722) |
|
5,297 |
|
Equity issuance cost extinguishment2 |
|
— |
|
1,078 |
|
— |
|
1,078 |
|
Non-GAAP adjusted (loss) |
|
|
|
|
|
|
|
|
|
Basic and Diluted shares outstanding |
|
190,945 |
|
108,176 |
|
171,575 |
|
92,131 |
|
Non-GAAP adjusted (loss) income per share |
|
|
|
|
|
|
|
|
|
|
|
1 Included in general and administrative expenses in the financial statements. |
|
2 Included in other income and expenses. |
|
3 Stock-based compensation ("SBC") expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses: |
|
|
|
(in thousands except per-share amounts) |
|
For the three months ended September 30, |
|
For the nine months ended September 30, |
||||
|
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
|
Cost of revenues |
|
|
|
|
|
|
|
|
|
Stock-based compensation expense3 |
|
(14) |
|
(43) |
|
(142) |
|
(152) |
|
Net cost of revenues |
|
1,390 |
|
1,654 |
|
4,332 |
|
4,658 |
|
|
|
|
|
|
|
|
|
|
|
Amortization of intangible assets |
|
105 |
|
105 |
|
315 |
|
316 |
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing |
|
5,252 |
|
4,291 |
|
16,029 |
|
12,367 |
|
Stock-based compensation expense3 |
|
(314) |
|
(268) |
|
(907) |
|
(753) |
|
Net sales and marketing |
|
4,938 |
|
4,023 |
|
15,122 |
|
11,614 |
|
|
|
|
|
|
|
|
|
|
|
General and administrative |
|
5,536 |
|
5,605 |
|
16,723 |
|
17,383 |
|
Depreciation expense |
|
(121) |
|
(115) |
|
(356) |
|
(347) |
|
Operating expenses issued in stock |
|
— |
|
(87) |
|
(57) |
|
(234) |
|
Stock-based compensation expense3 |
|
(949) |
|
(718) |
|
(3,024) |
|
(2,060) |
|
Net general and administrative |
|
4,466 |
|
4,685 |
|
13,286 |
|
14,742 |
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
1,182 |
|
1,272 |
|
3,581 |
|
3,955 |
|
Stock-based compensation expense3 |
|
(174) |
|
(123) |
|
(482) |
|
(361) |
|
Net research and development |
|
1,008 |
|
1,149 |
|
3,099 |
|
3,594 |
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
13,479 |
|
12,970 |
|
41,122 |
|
38,831 |
|
Depreciation and amortization expense |
|
(226) |
|
(220) |
|
(671) |
|
(663) |
|
Operating expenses issued in stock |
|
— |
|
(87) |
|
(57) |
|
(234) |
|
Stock-based compensation expense3 |
|
(1,451) |
|
(1,152) |
|
(4,555) |
|
(3,326) |
|
Net operating expenses |
|
|
|
|
|
|
|
|
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing esophageal cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-provides-business-update-and-reports-third-quarter-2026-financial-results-302937794.html
SOURCE Lucid Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Lucid Diagnostics' third-quarter 2026 revenue and earnings?
Lucid reported $1.203 million in revenue and a net loss attributable to common stockholders of $6.677 million, or $0.03 per share. A year earlier, revenue was $1.211 million and the common-stockholder net loss was $10.397 million, or $0.10 per share.
How is Medicare paying for Lucid Diagnostics' EsoGuard test?
Medicare coverage operates through claim-by-claim adjudication, independently of the pending MolDX local coverage determination reconsideration. Lucid began submitting claims in late September after meeting with Novitas medical directors and providing a clinical evidence dossier incorporating their feedback. Payments began in October at the established Clinical Laboratory Fee Schedule rate of $1,938.01 per test.
What billing and coding changes did Lucid Diagnostics announce for EsoGuard and EsoCheck?
The milestones include a new Category III CPT code for EsoCheck cell collection and a proposed ICD-10 diagnosis code for positive EsoGuard results. Lucid expects these changes to make the products easier to bill, track and integrate into clinical practice.